Abstract
Background Ketone bodies are metabolites produced during fasting or on a ketogenic diet that have pleiotropic effects on the inflammatory and metabolic aging pathways underpinning frailty in in vivo models. Ketone esters (KEs) are compounds that induce hyperketonemia without dietary changes and that may impact physical and cognitive function in young adults. The functional effects of KEs have not been studied in older adults.
Objectives Our long-term goal is to examine if KEs modulate aging biology mechanisms and clinical outcomes relevant to frailty in older adults. Here, we report the exploratory functional and quality-of-life outcome measures collected during a 12-week safety and tolerability study of KE (NCT05585762).
Design Randomized, placebo-controlled, double-blinded, parallel-group, pilot trial of 12-weeks of daily KE ingestion.
Setting The Clinical Research Unit at the Buck Institute for Research on Aging, California. Participants: Community-dwelling older adults (≥ 65 years), independent in activities of daily living, with no unstable acute medical conditions (n = 30).
Intervention Subjects were randomly allocated (1:1) to consume 25 g daily of either KE (bis-octanoyl (R)-1,3-butanediol) or a taste, appearance, and calorie-matched placebo (PLA) containing canola oil.
Measurements Longitudinal change in physical function, cognitive function and quality of life were assessed as exploratory outcomes in n = 23 completers (n = 11 PLA, n = 12 KE). A composite functional outcome to describe the vigor-frailty continuum was calculated. Heart rate and activity was measured throughout the study using digital wearables.
Results There were no statistically significant longitudinal differences between groups in exploratory functional, activity-based or quality of life outcomes.
Conclusion Daily ingestion of 25 g of KE did not affect exploratory functional or quality-of-life end points in this pilot cohort of healthy older adults. Future work will address these endpoints as primary and secondary outcomes in a larger trial of pre-frail older adults.
Competing Interest Statement
The Buck Institute holds shares in BHB Therapeutics (Ireland) and Selah Therapeutics. B.J.S. has stock in H.V.M.N Inc, and stock options in Selah Therapeutics Ltd, BHB Therapeutics (Ireland) Ltd., and Juvenescence Ltd. J.C.N. has stock options in Selah Therapeutics Ltd and BHB Therapeutics (Ireland) Ltd. J.C.N and B.J.S. are inventors on patents related to the use of ketone bodies that are assigned to The Buck Institute. Individual and institutional conflict management plans were developed and approved by the Buck Institute and submitted to the reviewing IRB. Actions and decisions important to participant safety and study integrity were carried out by honest brokers with no potential financial conflict. Participant consent was obtained by licensed registered nurses (L.A and W.S.M) who have no financial conflict. Decisions on participant enrollment, continuation, and were made by independent medical officers (J.M and M.Y) unaffiliated with Buck Institute and with no financial conflict. All other authors have no conflicts to report.
Clinical Trial
NCT05585762
Funding Statement
Funding for the study was provided by philanthropic donations from Dr. James B. Johnson and from members of the Buck Institute Impact Circle. Dr. Johnson assisted with conceptualization of the study and reviewed this manuscript but has no further role in study design, management, data collection, analysis, interpretation of data, decision to submit publications, or writing of publications. The Buck Institute Impact Circle had no role in conceptualization, study design, management, data collection, analysis, interpretation of data, decision to submit publications, review, or writing of publications. Dr. Newmans participation in the study was supported by Buck Institute institutional funds. Dr. Brianna Stubbs participation in the study was supported by the NIH (NIA) under award number K01AG078125. The KE intervention was provided gratis by BHB Therapeutics Ltd (Ireland). BHB Therapeutics also arranged for manufacture of the matched placebo, paid for by study funds. BHB Therapeutics (Ireland) markets formulated KE beverages to consumers. BHB Therapeutics (Ireland) provided no funding for the study, and had no role in the design, management, data collection, analysis, interpretation of data, decision to submit publications, or writing of publications.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by Advarra IRB on September 28th 2022 (Pro00065464)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Clinicaltrials.gov registration number: NCT05585762
Current protocol version number and date: version 1.3, approved on 16th October 2023
Data Availability Statement
The data presented here may be available upon reasonable request from the corresponding author and in accordance with intellectual property considerations.
Abbreviations
- 1-RM
- 1 Repetition Maximum
- ADL
- Activities of Daily Living
- AEs
- Adverse Events
- BDO
- (R)-1,3-butanediol
- BH-BD
- Bis-hexanoyl (R)-1,3-butanediol
- ΒHB
- Beta-hydroxybutyrate
- BMI
- Body Mass Index
- BO-BD
- Bis-octanoyl (R)-1,3-butanediol
- BTQ
- Beverage Tolerability Questionnaire
- CSHA
- Canadian Study of Health and Aging
- CRF
- Case Report Form
- DSST
- Digit Symbol Substitution Test
- IADL
- Instrumental Activities of Daily Living
- ITT
- Intention to treat
- KEs
- Ketone Esters
- MoCA
- Montreal Cognitive Assessment
- PLA
- Placebo
- PP
- Per protocol
- QoL
- Quality of Life
- SASP
- Senescence-associated Secretory Phenotype
- SPPB
- Short Physical Performance Battery
